gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · KRYSHealthcareBiotechnology

Krystal Biotech, Inc. Common Stock (KRYS)

$310.84+1.90%
Close Nov 4, 2026 · split-adjusted
Nov 2, 2026$295.90▲ 49.56% in range
Nov 3, 2025Low $197.85 · High $378.15Nov 2, 2026
What changed · written from our data
As of Nov 4, 2026

Krystal Biotech closed at $310.84 on Nov 4, up 1.90%, 17.8% below its 52-week closing high. Volume of 414.3K shares was 1.29× its 20-day average (above normal).

Split-adjusted performance: -4.9% over one month, +7.6% over six months, +57.1% over one year.

In the quarter ended Sep 30, 2026, revenue was $127.34M, up 30.2% from a year earlier, with a net margin of 49.5%.

Short interest was 2.9M shares at the Oct 15 settlement, down 15.5% from the prior report (12.9% of float, 10.3 days to cover).

Market cap$9.20B29.6M shares
Revenue · quarter$127.3M+30.2% YoY
Diluted EPS$2.05−22.9% YoY
P/E · TTM40.9×P/S 19.6×
Net margin49.5%Gross 94.1%
Dividend yieldNone
52-week range197.85 – 378.15−17.8% from high
Volume414.3K1.29× 20-day avg
Volatility · 60d39.1%Annualised
Short % of float12.9%10.3 days to cover
Net cash$911.9MCash $911.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −3.3%1M −4.9%3M −3.7%6M +7.6%YTD +26.1%1Y +57.1%3Y +167.1%5Y +485.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum72
Revenue growth69
Net margin94
Value (low P/E)23
Size90

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short2.9M−15.5% vs prior
Days to cover10.3Settled Oct 15
% of float12.9%
Short vol. 10d72.1%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
KRYSKrystal Biotech$310.84+1.90%+7.6%+30.2%49.5%40.9$9.20B
TWSTTwist Bioscience$142.58+1.63%+139.5%+23.2%−29.6%—$9.45BCompare
IBRXImmunityBio$8.93+7.72%+6.6%+93.9%−449.6%—$9.46BCompare
PCVXVaxcyte$65.68+8.01%+15.0%———$10.34BCompare
RGENRepligen$178.20−0.04%+41.7%+10.9%−18.4%—$11.31BCompare
TECHBio-Techne$72.73+0.10%+53.4%+1.3%17.0%62.8$11.42BCompare
KYMRKymera Therapeutics$136.25+7.21%+58.0%−100.0%——$11.63BCompare
KODKodiak Sciences$98.51−0.38%+114.7%———$6.19BCompare
IMVTImmunovant$29.90+2.96%+4.3%———$6.18BCompare

News about Krystal Biotech

All news →
Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue EstimatesZacks Investment Research · 2d ago▼ NegativeAnalysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out forZacks Investment Research · Oct 26, 2026▼ NegativeKRYS Reports Positive Early Data for KB113 in Gorlin SyndromeZacks Investment Research · Oct 16, 2026▲ PositiveKrystal Biotech to Present at 2026 Cantor Global Healthcare ConferenceGlobeNewswire Inc. · Sep 3, 2026▲ PositiveKrystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?Zacks Investment Research · Sep 2, 2026Neutral

Quick answers

What does Krystal Biotech do?
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells.
What is KRYS's market cap?
$9.20B, based on the Nov 4 close of $310.84.
What is KRYS's P/E ratio?
40.9× trailing-twelve-month earnings of $225.17M.
Does Krystal Biotech pay a dividend?
No regular cash dividend has been paid in the last year.
How much of KRYS is sold short?
2.9M shares, 12.9% of float, as of Oct 15, 2026.
What sector is KRYS in?
Healthcare, in the Biotechnology industry.

About Krystal Biotech

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

HQ: Pittsburgh, PA295 employeesListed Sep 20, 2017krystalbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology